La presentazione è in caricamento. Aspetta per favore

La presentazione è in caricamento. Aspetta per favore

Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano,

PubblicatoCesare Ricardo Roberti Modificato 8 anni fa

Presentazioni simili

Presentazione sul tema: "Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano,"— Transcript della presentazione:

1 Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano, Giuseppina Calvaruso, Rosario Di Maggio, Massimiliano Sacco, Alessandra Quota, Marcello Capra, Aldo Filosa, Domenico Giuseppe D'Ascola, Carmelo Fidone, Antonella Carollo, Lorella Pitrolo, Calogera Gerardi, Grazia Colletti, Gaetano Roccamo, Maria Antonietta Romeo, Paolo Cianciulli, Maria-Eliana Lai, Luciana Concetta Rigoli, Gianluca Forni, and Aurelio Maggio Blood Volume 124(21):1354-1354 December 6, 2014 ©2014 by American Society of Hematology

2 Estimated profiles of the mean serum ferritin in the two treatment-groups from the fitted linear mixed-effects model. Angela Vitrano et al. Blood 2014;124:1354 ©2014 by American Society of Hematology

3 Kaplan–Meier survival probability curves in the two treatment groups during multi-center TI clinical trial (DFP: continous line; DFO: dashed line), (p-value=0.36). Angela Vitrano et al. Blood 2014;124:1354 ©2014 by American Society of Hematology

Scaricare ppt "Deferiprone Versus Deferoxamine in Thalassemia Intermedia: Results from 5-Year Long-Term Italian Multi- Center Randomized Clinical Trial by Angela Vitrano,"

Presentazioni simili

I C I A II A II B I B ELENCO ALUNNI V A III A III B V B IV A IV B.

I C I A II A II B I B ELENCO ALUNNI V A III A III B V B IV A IV B.
ELENCO DOCENTI Aliotta Maria Lo Iacono M.Ter Davì Maria

ELENCO DOCENTI Aliotta Maria Lo Iacono M.Ter Davì Maria
FUNZIONI STRUMENTALI AL POF REFERENTI AREA DIDATTICA

FUNZIONI STRUMENTALI AL POF REFERENTI AREA DIDATTICA
Alfano - Sciandra - Montagna.

Alfano - Sciandra - Montagna.
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia by Andrea Pession, Riccardo Masetti,

Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia by Andrea Pession, Riccardo Masetti,
Emilin1 Links TGF-β Maturation to Blood Pressure Homeostasis Luca Zacchigna, Carmine Vecchione, Antonella Notte, Michelangelo Cordenonsi, Sirio Dupont,

Emilin1 Links TGF-β Maturation to Blood Pressure Homeostasis Luca Zacchigna, Carmine Vecchione, Antonella Notte, Michelangelo Cordenonsi, Sirio Dupont,
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the.

Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the.
Luigi Pirandello Il figlio del Caos 03. 77 1898 Luigi e Antonietta con il primogentito Stefano. La sorella Lina con il marito Calogero e le loro bambine.

Luigi Pirandello Il figlio del Caos Luigi e Antonietta con il primogentito Stefano. La sorella Lina con il marito Calogero e le loro bambine.
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation by Mauro Di Ianni, Franca Falzetti, Alessandra Carotti, Adelmo.

Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation by Mauro Di Ianni, Franca Falzetti, Alessandra Carotti, Adelmo.
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria.

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study by Sara Bringhen, Maria.
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella.

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella.
Additional chromosomal abnormalities in Philadelphia- positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party.

Additional chromosomal abnormalities in Philadelphia- positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party.
Identification of a New Locus for Medullary Cystic Disease, on Chromosome 16p12 Francesco Scolari, Daniela Puzzer, Antonio Amoroso, Gianluca Caridi, Gian.

Identification of a New Locus for Medullary Cystic Disease, on Chromosome 16p12 Francesco Scolari, Daniela Puzzer, Antonio Amoroso, Gianluca Caridi, Gian.
Problematiche nutrizionali nell ʼ adulto e nell ʼ anziano: paziente con BPCO e paziente con diabete. Dr. V. Emanuele.

Problematiche nutrizionali nell ʼ adulto e nell ʼ anziano: paziente con BPCO e paziente con diabete. Dr. V. Emanuele.
TERAPIA COMBINATA DEFERASIROX + DESFERIOXAMINA IN UN CASO DI GRAVE SIDEROSI CARDIACA ED EPATICA CON DISFUNZIONE CARDIACA: NORMALIZZAZIONE DEI DEPOSITI.

TERAPIA COMBINATA DEFERASIROX + DESFERIOXAMINA IN UN CASO DI GRAVE SIDEROSI CARDIACA ED EPATICA CON DISFUNZIONE CARDIACA: NORMALIZZAZIONE DEI DEPOSITI.
PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression.

PET/CT Is a Useful Tool For Both Refining The Definition Of Complete Response (CR) In Multiple Myeloma (MM) and Detecting Otherwise Unrevealed Progression.
Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation.

Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation.
Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo.

Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo.
Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis by Fausto Castagnetti, Gabriele.

Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis by Fausto Castagnetti, Gabriele.
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia by Luca Malcovati, Elli Papaemmanuil, Ilaria Ambaglio,

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia by Luca Malcovati, Elli Papaemmanuil, Ilaria Ambaglio,

Presentazioni simili

Annunci Google